Merck (MRK) Other Non-Current Assets (2009 - 2026)
Merck (MRK) posted quarterly Other Non-Current Assets of $19.8 billion for Q1 2026, up 18.12% year-over-year from $16.8 billion in Q1 2025, and up 5.25% quarter-over-quarter from $18.8 billion in Q4 2025.
Merck (MRK) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Other Non-Current Assets for 16 consecutive years, with $19.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 18.12% year-over-year to $19.8 billion; the TTM figure through Mar 2026 stood at $19.8 billion (up 18.12% YoY), while the FY2025 annual figure was $18.8 billion, up 17.29% from the prior year.
- Other Non-Current Assets improved to $19.8 billion in Q1 2026 per MRK's latest filing, from $18.8 billion in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $19.8 billion in Q1 2026 and bottomed at $69.0 million in Q2 2023.
- Historically, Other Non-Current Assets has averaged $11.3 billion across 5 years, with a median of $12.5 billion in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 28975.0% — and 2023, when it slumped 74.12%.
- Merck's Other Non-Current Assets stood at $9.5 billion in 2022, then gained by 25.9% to $12.0 billion in 2023, then soared by 33.74% to $16.0 billion in 2024, then advanced by 17.29% to $18.8 billion in 2025, then rose by 5.25% to $19.8 billion in 2026.
- Business Quant data shows MRK's Other Non-Current Assets at $19.8 billion in Q1 2026, $18.8 billion in Q4 2025, and $18.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 5.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.60 Bn |
| Mar 31, 2026 | 19.81 Bn |
| Dec 31, 2025 | 18.82 Bn |
| Sep 30, 2025 | 18.33 Bn |
| Jun 30, 2025 | 17.66 Bn |
| Mar 31, 2025 | 16.77 Bn |
| Dec 31, 2024 | 16.04 Bn |
| Sep 30, 2024 | 14.44 Bn |
| Jun 30, 2024 | 12.70 Bn |
| Mar 31, 2024 | 12.33 Bn |
| Dec 31, 2023 | 12.00 Bn |
| Sep 30, 2023 | 10.56 Bn |
| Jun 30, 2023 | 69.00 Mn |
| Mar 31, 2023 | 301.00 Mn |
| Dec 31, 2022 | 9.53 Bn |
| Sep 30, 2022 | 323.00 Mn |
| Mar 31, 2022 | 1.16 Bn |
| Mar 31, 2021 | 4.00 Mn |
| Dec 31, 2020 | 3.18 Bn |
| Mar 31, 2020 | 62.00 Mn |